• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Pfizer (PFE)

With a history that can be traced all the way back to 1849, Pfizer is a mega-cap pharmaceutical and biotechnology company. The pandemic made it even more well-known globally.

Over 3.6 billion Pfizer-BioNTech COVID-19 vaccines have been shipped to 180 countries worldwide. Meanwhile, Pfizer is also the developer of Paxlovid, an oral antiviral pill used to treat COVID-19.

The company reported strong results this earnings season. For Q2, Pfizer generated $27.7 billion of revenue, representing a 47% increase year-over-year. Adjusted earnings per share came in at $2.04, up 92% from the year-ago period.

The stock, however, is not immune to the market sell-off in 2022. Year-to-date, Pfizer shares have slipped 12%.

JPMorgan analyst Chris Schott has a ‘neutral’ rating on Pfizer and a price target of $57 — roughly 15% above where the stock sits today.

Meet Your Retirement Goals Effortlessly

The road to retirement may seem long, but with WiserAdvisor, you can find a trusted partner to guide you every step of the way

WiserAdvisor matches you with vetted financial advisors that offer personalized advice to help you to make the right choices, invest wisely, and secure the retirement you've always dreamed of. Start planning early, and get your retirement mapped out today.

Get Started

Gilead Sciences (GILD)

Gilead Sciences is another biopharmaceutical company that made headlines during the pandemic. It is the developer of Veklury (remdesivir), the first antiviral drug approved by the FDA for the treatment of COVID-19 requiring hospitalization.

The company reported Q2 earnings on Tuesday. For the quarter, revenue edged up 1% year-over-year to $6.3 billion. Adjusted earnings per share declined 13% year over year to $1.58.

While these numbers don’t look impressive on their own, they smashed Wall Street’s expectations. On average, analysts expected Gilead to report earnings of $1.52 per share on $5.86 billion of revenue for the quarter.

Management also boosted their guidance. For full-year 2022, they expect the company to earn $24.5 billion to $25 billion in total product sales, up from their previous guidance range of $23.8 billion to $24.3 billion.

The stock shot up 4.6% on Wednesday. However, it’s still down 14% year to date.

Piper Sandler analyst Do Kim recently reiterated a ‘neutral’ rating on Gilead while raising the price target from $69 to $71. Considering that Gilead trades at $62.27 today, the price target implies a potential upside of 14%.

Abbott Laboratories (ABT)

Abbott Laboratories is a healthcare company that specializes in medical devices, diagnostics, nutrition products, and branded generic medicines.

Like the other two companies, Abbott hasn’t been a hot ticker. Its shares have fallen a painful 21% in 2022.

But the company is solidly-positioned for another wave of COVID-19 – it makes COVID-19 testing kits.

According to the latest earnings report, COVID-19 testing-related sales amounted to $2.3 billion for Abbott in Q2 of 2022.

Sales totaled $11.3 billion for the quarter, representing a 10.1% increase year over year. Adjusted earnings per share grew 22.2% from a year ago to $1.43.

Management expects the company to earn $6.1 billion in COVID-19 testing-related sales in full-year 2022.

Citi analyst Joanne Wuensch has a ‘buy’ rating on Abbott and a price target of $123 — around 12% above the current levels.


Follow These Steps if you Want to Retire Early

Secure your financial future with a tailored plan to maximize investments, navigate taxes, and retire comfortably.

Zoe Financial is an online platform that can match you with a network of vetted fiduciary advisors who are evaluated based on their credentials, education, experience, and pricing. The best part? - there is no fee to find an advisor.

About the Author

Jing Pan

Jing Pan

Investment Reporter

Jing is an investment reporter for MoneyWise. He is an avid advocate of investing for passive income. Despite the ups and downs he’s been through with the markets, Jing believes that you can generate a steadily increasing income stream by investing in high quality companies.

What to Read Next


The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.